Advanced search
Publication Cover
International Journal of Nanomedicine Volume 16, 2021 - Issue
Submit an article Journal homepage
90
Views
0
CrossRef citations to date
0
Altmetric
Original Research

Biodegradable Materials with Disulfide-Bridged-Framework Confine Photosensitizers for Enhanced Photo-Immunotherapy

Dongbei Li1 Department of Hematology, Affiliated Tumor Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou City, Henan Province, People’s Republic of China
,
Fangman Chen2 School of Biomedical Engineering (Suzhou), Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, 230026, People’s Republic of China
,
Cheng Cheng1 Department of Hematology, Affiliated Tumor Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou City, Henan Province, People’s Republic of China
,
Haijun Li3 Department of Clinical Laboratory, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, 450052, People’s Republic of China
&
Xudong Wei1 Department of Hematology, Affiliated Tumor Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou City, Henan Province, People’s Republic of ChinaCorrespondence[email protected] [email protected]
Pages 8323-8334 | Published online: 24 Dec 2021

Figures & data

Figure 1 Preparation and characterization of SSNs.

Notes: (A) TEM and (B) EDX mapping images of SSNs. (C) EDX mapping images of SSNs. (D) absorbance spectra of free Ce6 and SSNs@Ce6. (E) Emission spectra of Ce6 and SSNs@Ce6.
Abbreviations: TEM, transmission electron microscopy; EDX, energy dispersive X-ray spectroscopy; SSNs, disulfide-bond-bridged organosilica nanoparticles; FL, fluorescein; SSNs@FL, fluorescein-loading disulfide-bond-bridged organosilica nanoparticles; AD, adriamycin; SSNs@AD, adriamycin-loading disulfide-bond-bridged organosilica nanoparticles; Ce6, chlorin e6; SSNs@Ce6, chlorin e6-loading disulfide-bond-bridged organosilica nanoparticles.
Figure 1 Preparation and characterization of SSNs.

Figure 2 Extracellular GSH depletion assay and extracellular ROS detection.

Notes: Degradation of (A) SSNs@Ce6 and (B) SNs@Ce6 in 10 mM GSH solution. (C) GSH depletion of free Ce6, SNs@Ce6 and SSNs@Ce6. (D) ROS generation of free Ce6, SNs@Ce6 and SSNs@Ce6 upon 660 nm light irradiation. Scar bar repesents 100 μm.
Abbreviations: GSH, glutathione; ROS, radical oxygen species; Ce6, chlorin e6; SNs, inorganic silica nanocarrier; SNs@Ce6, chlorin e6-loading inorganic silica nanocarrier; SSNs@Ce6, chlorin e6-loading disulfide-bond-bridged organosilica nanoparticles.
Figure 2 Extracellular GSH depletion assay and extracellular ROS detection.

Figure 3 Fluorescence imaging and quantitative analysis in 4T1.

Notes: (A) Fluorescence imaging of cellular uptake of SSNs@Ce6 and free Ce6 in 4T1. (B) Quantitative analysis of the internalization of SSNs@Ce6 and free Ce6 in 4T1.
Abbreviations: Ce6, chlorin e6; SSNs@Ce6, chlorin e6-loading disulfide-bond-bridged organosilica nanoparticles.
Figure 3 Fluorescence imaging and quantitative analysis in 4T1.

Figure 4 Intracellular GSH depletion ROS generation assay in 4T1.

Notes: Quantitative analysis of (A) GSH depletion and (B) ROS generation in 4T1 cells. (C) Fluorescence imaging of ROS generation in 4T1 cells.
Abbreviations: GSH, glutathione; ROS, radical oxygen species.
Figure 4 Intracellular GSH depletion ROS generation assay in 4T1.

Figure 5 Cytotoxicity, ICD effect and DC maturation in vitro.

Notes: (A) Cytotoxicity of free Ce6, SNs@Ce6 and SSNs@Ce6 against 4T1 cells with light irradiation (0.1 W cm−2, 10 min) after 24 h incubation. (B) Percentage of CRT-positive cells and (C) amount of released HMGB1 after 24 h. (D) Percentage of mature DCs (CD11c+CD80+CD86+) after co-incubation with 4T1 cells with different treatments for 24 h.
Abbreviations: Ce6, chlorin e6; SNs, inorganic silica nanocarrier; SNs@Ce6, chlorin e6-loading inorganic silica nanocarrier; SSNs@Ce6, chlorin e6-loading disulfide-bond-bridged organosilica nanoparticles; CRT, calreticulin.
Figure 5 Cytotoxicity, ICD effect and DC maturation in vitro.

Figure 6 In vivo experiments.

Notes: (A) Blood circulation time of free Ce6, SNs@Ce6 and SSNs@Ce6 in 4T1-tumor-bearing mice. (B) Accumulation of SSNs@Ce6 in tumor tissue. (C) Tumor volume and (D) tumor weight after treating with formulations in 4T1-tumor-bearing mice.
Abbreviations: Ce6, chlorin e6; SNs, inorganic silica nanocarrier; SNs@Ce6, chlorin e6-loading inorganic silica nanocarrier; SSNs@Ce6, chlorin e6-loading disulfide-bond-bridged organosilica nanoparticles.
Figure 6 In vivo experiments.

Figure 7 Biosafety profile.

Notes: (A) Body weight, (B) ALT, (C) AST, (D) LDH, (E) CK, and (F) BUN.
Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; BUN, blood urea nitrogen; LDH, lactate dehydrogenase; CK, creatinine kinase.
Figure 7 Biosafety profile.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.